No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia

Neuropsychobiology

Volumn 55, Issue 1, 2007, Pages 47-51

  Lee, Heon Jeong ^a   Kang, Seung Gul ^a   Choi, Jung Eun ^a   Paik, Jong Woo ^a   Kim, Yong Ku ^a   Kim, Seung Hyun ^a   Lee, Min Soo ^a   Joe, Sook Haeng ^a   Jung, In Kwa ^a   Kim, Leen ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Dopamine D4 receptor; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

DOPAMINE 4 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TARDIVE DYSKINESIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA;

EID: 34347207196     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103576     Document Type: Article

References (36)

1. Kane JM, Smith JM: Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481.
2. Sachdev PS: The current status of tardive dyskinesia. Aust NZ J Psychiatry 2000;34:355-369.
3. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N: Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990;102:474-478.
4. Yassa R, Ananth J: Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618-1619.
5. Tarsy D, Baldessarini RJ: The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12:431-450.
6. Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(suppl B):47-52.
7. Casey DE, Gerlach J, Magelund G, Christensen TR: gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376-1379.
8. Chen CH, Wei FU, Koong FJ, Hsiao KJ: Association of Taq I A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-829.
9. Chong SA, Tan EC, Tan CH, Mythily, Chan YH: Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;116:51-54.
10. Steen VM, Lovlie R, MacEwan T, McCreadie RG: Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-145.
11. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B: Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247-253.
12. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, Mc-Creadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietsche lM, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.
13. Rietschel M, Krauss H, Muller DJ, Schulze TG, Knapp M, Marwinski K, Maroldt AO, Paus S, Grunhage F, Propping P, Maier W, Held T, Nothen MM: Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000;250:31-35.
14. Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E: Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004;7:489-493.
15. Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M, Yakir A, Greenberg D, Strous R, Lerner A, Shelevoy A, Lerer B: Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3:277-283.
16. Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, BK T: Genetic susceptibility to tardive dyskinesia among schizophrenia subjects. IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111-117.
17. Okuyama Y, Ishiguro H, Toru M, Arinami T: A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 1999;258:292-295.
18. Okuyama Y, Ishiguru H, Nankai M, Shibuya H, Watanabe A, Arinami T: Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry 2000;5:64-69.
19. Ronai Z, Szekely A, Nemoda Z, Lakatos K, Gervai J, Staub M, Sasvari-Szekely M: Association between novelty seeking and the -521 C/T polymorphism in the promoter region of the DRD4 gene. Mol Psychiatry 2001;6:35-38.
20. Lee HJ, Lee HS, Kim YK, Kim SH, Kim L, Lee MS, Joe SH, Jung IK, Suh KY, Kim S: Allelic variants interaction of dopamine receptor D4 polymorphism correlate with personality traits in young Korean female population. Am J Med Genet B Neuropsychiatr Genet 2003;118:76-80.
21. Han OS, Hong JP: Structured Clinical Interview for DSM-IV Axis I Disorder - Korean Version. Seoul, Hana Medical Publishing, 2000.
22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
23. Stoll AL: The Psychopharmacology Reference Card. Antipsychotic Treatment Guide. Belmont, McLean Hospital, 1998.
24. Schooler NR, Kane JM: Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
25. Guy W: ECDEU Assessment Manual for Psychopharmacology, rev ed. Washington, Department of Health, Education and Welfare, 1976.
26. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
27. Ronai Z, Barta C, Guttman A, Lakatos K, Gervai J, Staub M, Sasvari-Szekely M: Genotyping the -521C/T functional polymorphism in the promoter region of dopamine D4 receptor (DRD4) gene. Electrophoresis 2001;22:1102-1105.
28. Binder RL, Kazamatsuri H, Nishimura T, McNiel DE: Smoking and tardive dyskinesia. Biol Psychiatry 1987;22:1280-1282.
29. Yassa R, Lal S, Korpassy A, Ally J: Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.
30. Andersson K, Fuxe K, Agnati LF: Effects of single injections of nicotine on the ascending dopamine pathways in the rat: evidence for increases of dopamine turnover in the mesostriatal and mesolimbic dopamine neurons. Acta Physiol Scand 1981;112:345-347.
31. Cadet JL, Lohr JB, Jeste DV: Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-108.
32. Held T, Weber T, Krausz H, Ahle G, Hager B, Alfter D, Schulze T, Knapp M, Maier W, Rietschel M: Clinical characteristics of patients with tardive dyskinesias. Fortschr Neurol Psychiatr 2000;68:321-331.
33. Chouinard G: Interrelations between psychiatric symptoms and drug-induced movement disorder. J Psychiatry Neurosci 2006;31:177-180.
34. Shale H, Tanner C: Pharmacological options for the management of dyskinesias. Drugs 1996;52:849-860.
35. Gorwood P: Genetic association studies in behavioral neuroscience; in Cruzio W, Gerlai R (eds): Molecular Genetic Techniques for Behavioral Neuroscience. Amsterdam, Elsevier, 1999, pp 113-121.
36. Kim JW: Association study and the population admixture; in Lee MS (ed): Human Neurobehavioral Genetics in the 21st Century - Winter Workshop. Seoul, Korean Society of Biological Psychiatry, 2000.